Retrospective analysis assesses infection risk in PHA cranioplasty, indicating management strategies to avoid explantation.
Background/Objectives: Postoperative infection is a significant complication following cranioplasty procedures. This study aimed to assess infection risk factors and clinical outcomes in patients undergoing cranioplasty with custom-made porous hydroxyapatite (PHA) implants, with a particular focus on treatment strategies used to manage infections and avoid implant explantation. Methods: This retrospective multicenter analysis included 984 patients who underwent PHA cranioplasty as part of a post-market clinical follow-up. Clinical data included demographics, surgical characteristics, infection features, microbiological results, infection management strategies, and outcomes. Associations with infection risk and implant explantation were assessed using chi-square tests. Results: Seventy-six patients (7.7%) developed postoperative infections. Infection risk was significantly associated with second-line procedures (p = 0.011) and implant location (p = 0.037). Most infections were superficial (92.1%) and early-onset (≤2 months from the surgery, 61.9%), with Staphylococcus spp. as the predominant pathogens. Explantation occurred in 77.6% of infected cases. The infection management strategy—whether initial conservative treatment with antibiotics alone (n = 18 of which 11.1% explanted) or surgical reoperation (n = 58 of which 93.8% explanted)—along with surgical cleaning and local (in situ) antibiotic use alone, was significantly associated with explantation outcomes (all p < 0.001). Among 18 patients treated with systemic antibiotics alone, 88.9% retained their implants. Notably, all successful cases had received broad-spectrum antibiotics for at least 4 weeks. Local antibiotic therapy was administered in 13 patients; no explants occurred among those who also received prolonged systemic treatment. Pathogen type was not significantly associated with the risk of explantation. Conclusions: Prolonged systemic antibiotic therapy, especially when combined with local treatment, may allow implant retention in selected infections, supporting individualized, conservative management strategies.
No takes yet. Share an insight, caveat, or question.
Mannella et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: